Sutherland D E, Matas A J, Goetz F C, Najarian J S
Diabetes. 1980;29 Suppl 1:31-44. doi: 10.2337/diab.29.1.s31.
Islet transplantation is successful in animals and holds considerable promise as endocrine replacement therapy for patients with diabetes mellitus, but clinical application to diabetic patients has been difficult. We have shown the technical feasibility of human islet transplantation by autotransplantation of dispersed pancreatic islet tissue into the portal vein in three patients with chronic pancreatitis and incapacitating, intractable pain who underwent near-total (greater than 97%) pancreatectomy. In all three patients, the excised pancreas was dispersed by collagenase digestion, but no effort was made to purify the islets. Islet yield, as judged by tissue insulin content, ranged from 24 to 55%. The first patient, who never received insulin after the pancreatectomy and islet autotransplantation, had a normal oral glucose tolerance test by 3 wk and has remained normoglycemic for over 2 yr. In the second patient, viable islets were histologically identified in the liver parenchyma. The third patient was treated with hyperalimentation for 3 wk after the pancreatectomy and islet autotransplantation and, during this period, required insulin. After cessation of hyperalimentation and initiation of oral geedings, the patient was withdrawn from insulin. Although abnormalities of carbohydrate metabolism were present, the patient did not require insulin for more than 1 yr. Seven diabetic renal allograft recipients have received allografts of dispersed pancreatic islet tissue prepared in the same way. No patients were cured of diabetes, although transient evidence of islet function--increase in serum or urinary C-peptide levels or decrease in exogenous insulin requirements--occurred in some. Although rejection was probably responsible for most of the failures, transplantation of allogeneic human islet tissue as a free graft is metabolically inefficient. With the current state of immunosuppressive therapy, the primary role of islet transplantation may be in a situation where rejection cannot occur: as an autograft to obviate the occurrence of diabetes after extensive pancreatectomy for benign disease.
胰岛移植在动物实验中取得成功,作为糖尿病患者的内分泌替代疗法具有很大前景,但在糖尿病患者中的临床应用一直困难重重。我们已通过将分散的胰腺胰岛组织自体移植到门静脉,向三名慢性胰腺炎且伴有致残性顽固性疼痛、接受了近全胰腺切除术(切除率大于97%)的患者展示了人胰岛移植的技术可行性。在这三名患者中,切除的胰腺均经胶原酶消化分散,但未对胰岛进行纯化。根据组织胰岛素含量判断,胰岛产量在24%至55%之间。第一名患者在胰腺切除和胰岛自体移植后从未接受过胰岛素治疗,术后3周口服葡萄糖耐量试验结果正常,且血糖正常已超过2年。第二名患者的肝实质中经组织学鉴定发现有存活的胰岛。第三名患者在胰腺切除和胰岛自体移植后接受了3周的肠外营养治疗,在此期间需要胰岛素。停止肠外营养并开始口服饮食后,该患者停用了胰岛素。尽管存在碳水化合物代谢异常,但该患者超过1年未再需要胰岛素。七名糖尿病肾移植受者接受了以同样方式制备的分散胰腺胰岛组织的同种异体移植。尽管部分患者出现了胰岛功能的短暂证据——血清或尿C肽水平升高或外源性胰岛素需求减少,但没有患者治愈糖尿病。尽管大多数移植失败可能是由排斥反应导致的,但作为游离移植物的同种异体人胰岛组织移植在代谢方面效率低下。就目前免疫抑制治疗的现状而言,胰岛移植的主要作用可能在于无法发生排斥反应的情况:作为自体移植以避免良性疾病广泛胰腺切除术后糖尿病的发生。